trans-AUCB Inhibitor

Name: trans-AUCB Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5755656
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5755656

trans-AUCB is an effective and selective soluble epoxide hydrolase inhibitor (IC50s: 1.3nM, 8nM, 8nM for hsEH, mouse sEH and rat sEH, respectively). More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

trans-AUCB, Inhibitor

Full Product Name

trans-AUCB

Product Gene Name

trans-AUCB, inhibitor

Product Synonym Names

t-AUCB

Form/Format

Solid. Powder

Purity/Purification

98.00%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

412.52

Solubility

DMSO: 250mg/mL (606.03mM) Need ultrasonic
(<1mg/ml refers to the product slightly soluble or insoluble)

Formula

C24H32N2O4

SMILES

OC(C(C=C1)=CC=C1O[C@@H](CC2)CC[C@H]2NC(NC34C[C@H](C5)C[C@H](C[C@H]5C4)C3)=O)=O

CAS Number

885012-33-9

Target & IC50

hsEH: ic50 1.3nM
mouse sEH: ic50 8nM
rat sEH: ic50 8nM

Product Categories/Family for trans-AUCB, inhibitor

Metabolism; Others

Product References and Citations for trans-AUCB, inhibitor

Liu JY, et al. Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murinemodel of inflammation. Br J Pharmacol. 2009 Jan;156(2):284-96.

Other Notes

Small volumes of trans-AUCB, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for trans-AUCB purchase

MBS5755656 is an inhibitor targeting trans-AUCB.